Proactive Investors - Run By Investors For Investors

efyian raising $1mln to refine its chlamydia & gonorrhea diagnostic device

efyian CEO Angelika Niemz updates Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

efyian’s goal is to improve patient health through rapid accurate infectious disease diagnosis at the point of care via molecular diagnostic testing devices. The company is developing a molecular diagnostic device that allows doctors to receive accurate results right away in their office.

View full EFYIA profile View Profile

efyian Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use